IN THE NEWS - oncohost

Media Coverage

30/03/2021

How an AI tool predicts responses to cancer treatment

Ofer Sharon, MD, CEO of OncoHost, spoke to Med-Tech Innovation News about its offering in oncology – and how its AI tool predicts responses to treatment.

22/03/2021

Revealing the Blind Spot in Cancer Treatment with Host Response Profiling

As cancer remains among the leading causes of death worldwide, with an estimated 1.8 million new cases diagnosed in 2020, scientists and doctors are fighting against the clock to find new therapeutic approaches to beat this rife disease.

04/02/2021

January 2021 smiles upon Israeli startups: 4 new Unicorns and over $1B in funding

26/01/2021

Health IT Appointments and Hires

To all Media Coverage >

News Releases

19/01/2021

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform

On a Mission to Match Individual Cancer Patients with the Most Effective Treatment, Investment will Expand Clinical Trials, Support Opening of a US Office and Preparation for Commercial Launch

11/01/2021

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board

Prof. Aaron Ciechanover Joins Host Response Profiling Company to Improve Precision Oncology and Overcome Resistance to Cancer Treatments

09/11/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020

Study Examines Plasma-Based Proteomic Profiling as a Clinically Insightful Tool for Oncologists to Identify New Targets in Overcoming Treatment Resistance

05/10/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO

Presentation to Focus on Host Response to Newly Approved Immune Checkpoint Inhibitors (ICIs) and How These Host Effects May Stratify Between Non-Small Cell Lung Cancer (NSCLC) Patients' Responsiveness to Immunotherapy.

To all News Releases >